Mitochondrial Dysfunction Underlies the Integrated Stress Response Activation in Ponatinib-Induced Cardiotoxicity
线粒体功能障碍是帕纳替尼诱导的心脏毒性中综合应激反应激活的基础
基本信息
- 批准号:10735043
- 负责人:
- 金额:$ 54.72万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-07-18 至 2028-06-30
- 项目状态:未结题
- 来源:
- 关键词:Adenosine TriphosphateAdultAffectApoptoticBCR geneBindingCancer BurdenCancer PatientCancer PrognosisCancer SurvivorCardiacCardiac MyocytesCardiotoxicityCardiovascular systemCell DeathCell LineCellsChronic Myeloid LeukemiaClinicalClustered Regularly Interspaced Short Palindromic RepeatsComplementComplexCoupledCouplesDataDefectDistressEIF-2alphaEffectivenessEventFDA approvedGatekeepingGenerationsGenesHeartHeart InjuriesHeart failureHumanImpairmentIn VitroIndividualInduction of ApoptosisInjuryInterventionK-562Knock-outKnowledgeLinkMaintenanceMalignant NeoplasmsMediatingMitochondriaModelingMolecularMusMutationMyocardial dysfunctionNamesOncologyOutcomeOxidation-ReductionOxidative StressPathogenicityPathologyPathway interactionsPatientsPharmaceutical PreparationsPhosphotransferasesPlayPrevalenceProtein BiosynthesisReactive Oxygen SpeciesResearch ProposalsResistanceRiskRoleSignal PathwaySignal TransductionStressStudy modelsTherapeuticTimeToxic effectTransgenic OrganismsTreatment EfficacyTreatment-Related CancerTyrosine Kinase InhibitorUp-Regulationbiological adaptation to stresscancer cellcardioprotectioncell typechronic myeloid leukemia cellclinically relevantextracellularimprovedin vivoinduced pluripotent stem cellinduced pluripotent stem cell derived cardiomyocytesinhibitorinnovationinsightknockout genemitochondrial dysfunctionmolecular targeted therapiesmortalitymouse modelneoplastic cellnoveloverexpressionpatient prognosispharmacologicprotective effectproteostasissmall moleculesuccesssystemic toxicitytherapeutic targettooltumortumor progression
项目摘要
PROJECT SUMMARY
There has been a significant decline in cancer related mortality, partly due to the emergence of molecular
targeted therapies. Unfortunately, the success of these drugs including tyrosine kinase inhibitors (TKIs) has been
tempered by a concomitant rise in the prevalence of cancer therapies-related cardiotoxicity. Ponatinib, a currently
FDA-approved third-generation TKI, is used to treat chronic myeloid leukemia (CML) patients carrying the
gatekeeper mutation breakpoint cluster region-Abelson (BCR-ABL) T315I. Despite its effectiveness, a
considerable number of patients receiving ponatinib suffers from various cardiac complications. Several studies
have linked ponatinib-induced cardiotoxicity to impaired pro-survival signaling pathways leading to cell death.
However, the molecular signaling pathways leading to these events remain obscure and a better understanding
of how cardiomyocytes respond to ponatinib may provide new insights into novel mitigation therapies. The heart
must adapt to stress conditions that occur as a result of intracellular or extracellular factors. The integrated stress
response (ISR) is one of the circuits responding to stress and serving to restore proteostasis by regulating protein
synthesis, although prolonged ISR activation leads to cell death. Whether the ISR is activated and plays a
protective or detrimental role in ponatinib-induced cardiotoxicity are largely unknown and may represent an
amenable therapeutic target which will be the focus of my current proposal. My preliminary data suggests that
ponatinib causes mitochondrial dysfunction in human induced pluripotent stem cell-derived cardiomyocytes
(hiPSC-CMs). Interestingly, mitochondrial damage appears to trigger activation of the ISR and is mediated by a
kinase called general control non-repressed 2 (GCN2). I also found that inhibition of the ISR using a novel small
molecule called ISR inhibitor (ISRIB) successfully blunted the cardiotoxic effects of ponatinib both in vitro and in
vivo. Hence, the central hypothesis of my proposal is that the ISR pathway which is activated upon sensing
mitochondrial damage plays a pivotal role in mediating ponatinib-induced cardiotoxicity. Aim 1 will investigate
whether activation of GCN2 couples mitochondrial damage to ISR activation upon impaired mitochondrial
reactive oxygen species (ROS) and adenosine triphosphate (ATP) level. Aim 2 will assess whether ponatinib
induces apoptosis and cardiac dysfunction through the GCN2/eIF2α/ATF4 axis. Lastly, aim 3 will explore whether
pharmacological suppression of the ISR even after the onset of ponatinib-induced cardiotoxicity remains
cardioprotective without compromising the efficacy of ponatinib against tumor cells. Taken together, at the
conclusion of these studies, we will have significantly expanded our knowledge by which how ponatinib-induced
mitochondrial dysfunction is sensed to trigger the ISR; whether this activation contributes to cardiac pathology;
and if crosstalk between these two pathways can be targeted as a therapeutic avenue to mitigate ponatinib-
induced cardiotoxicity clinically.
项目总结
与癌症相关的死亡率显著下降,部分原因是分子的出现。
有针对性的治疗。不幸的是,包括酪氨酸激酶抑制剂(TKIs)在内的这些药物的成功
随着癌症治疗相关心脏毒性流行率的上升而有所缓和。波纳替尼,目前的
FDA批准的第三代TKI,用于治疗携带
关守突变断点簇区-Abelson(BCR-ABL)T315I。尽管它很有效,但一个
接受波纳替尼治疗的患者中,有相当数量的患者患有各种心脏并发症。几项研究
已将波纳替尼诱导的心脏毒性与受损的促生存信号通路联系起来,从而导致细胞死亡。
然而,导致这些事件的分子信号通路仍然不清楚,而且人们对此有更好的理解
心肌细胞对波纳替尼的反应可能为新的缓解疗法提供新的见解。心脏
必须适应细胞内或细胞外因素造成的压力条件。综合压力
应答(ISR)是对应激作出反应并通过调节蛋白质来恢复蛋白平衡的回路之一
合成,尽管长时间的ISR激活会导致细胞死亡。ISR是否被激活并播放
在波纳替尼诱导的心脏毒性中的保护或有害作用在很大程度上是未知的,可能代表着一种
顺从的治疗目标,这将是我目前提议的重点。我的初步数据显示
波那替尼引起人诱导的多能干细胞来源的心肌细胞线粒体功能障碍
(HiPSC-CMS)。有趣的是,线粒体损伤似乎触发了ISR的激活,并通过一种
被称为一般对照非抑制因子2(GCN2)的激酶。我还发现,抑制ISR使用的是一种新颖的小
一种名为ISR抑制剂(ISRIB)的分子在体外和体内成功地钝化了波纳替尼的心脏毒性作用
活着。因此,我的建议的中心假设是,在感知时激活的ISR通路
线粒体损伤在介导波纳替尼诱导的心脏毒性中起着关键作用。AIM 1将调查
GCN2的激活是否将线粒体损伤与受损线粒体的ISR激活结合起来
活性氧(ROS)和三磷酸腺苷(ATP)水平。目标2将评估波纳替尼
通过GCN2/eIF2α/ATF4轴诱导细胞凋亡和心功能障碍。最后,《目标3》将探讨
即使在帕纳替尼诱导的心脏毒性开始后,ISR的药理抑制仍然存在
在不影响波纳替尼抗肿瘤细胞疗效的情况下保护心脏。放在一起,在
这些研究的结论,我们将大大扩展我们的知识,通过这些知识,波纳替尼是如何诱导
线粒体功能障碍被感知为触发ISR;这种激活是否有助于心脏病理;
如果这两条通路之间的串扰可以作为一种治疗途径来缓解帕纳替尼-
临床上出现心脏毒性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Won Hee Lee其他文献
Won Hee Lee的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 54.72万 - 项目类别:
Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 54.72万 - 项目类别:
Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 54.72万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 54.72万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 54.72万 - 项目类别:
Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 54.72万 - 项目类别:
Discovery Early Career Researcher Award
Laboratory testing and development of a new adult ankle splint
新型成人踝关节夹板的实验室测试和开发
- 批准号:
10065645 - 财政年份:2023
- 资助金额:
$ 54.72万 - 项目类别:
Collaborative R&D
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 54.72万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 54.72万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 54.72万 - 项目类别:
Grant-in-Aid for Scientific Research (C)